Evidence map›Paper›PMID 38495121›Full record

ArticleComputational and structural biotechnology journal2024

miR-21 Responsive Nanocarrier Targeting Ovarian Cancer Cells.

Liting Han, Tao Song, Xinyu Wang, Yan Luo, Chuanqi Gu, Xin Li, Jinda Wen, Zhibin Wen, Xiaolong Shi

Abstract read
In one paragraph

Article in Computational and structural biotechnology journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Liting HanDepartment of Gynecology 2, Renmin Hospital of Wuhan University, Wuhan, China.
Tao SongCollege of Computer Science and Technology, China University of Petroleum (East China), Qingdao, China.
Xinyu WangDepartment of Gynecology 2, Renmin Hospital of Wuhan University, Wuhan, China.
Yan LuoDepartment of Gynecology 2, Renmin Hospital of Wuhan University, Wuhan, China.
Chuanqi GuDepartment of Gynecology 2, Renmin Hospital of Wuhan University, Wuhan, China.
Xin LiDepartment of Gynecology 2, Renmin Hospital of Wuhan University, Wuhan, China.
Jinda WenInstitute of Computing Science and Technology, Guangzhou University, Guangzhou, China.
Zhibin WenInstitute of Computing Science and Technology, Guangzhou University, Guangzhou, China.
Xiaolong ShiInstitute of Computing Science and Technology, Guangzhou University, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years, DNA origami-based nanocarriers have been extensively utilized for efficient cancer therapy. However, developing a nanocarrier capable of effectively protecting cargos such as RNA remains a challenge. In this study, we designed a compact and controllable DNA tubular origami (DTO) measuring 120 nm in length and 18 nm in width. The DTO exhibited appropriate structural characteristics for encapsulating and safeguarding cargo. Inside the DTO, we incorporated 20 connecting points to facilitate the delivery of cargoes to various ovarian and normal epithelial cell lines. Specifically, fluorescent-labeled DNA strands were attached to these sites as cargoes. The DTO was engineered to open upon encountering miR-21 through RNA/DNA strand displacement. Significantly, for the first time, we inhibited fluorescence using the compact DNA nanotube and observed dynamic fluorescent signals, indicating the controllable opening of DTO through live-cell imaging. Our results demonstrated that the DTO remained properly closed, exhibited effective internalization in ovarian cancer cells in vitro, showcasing marked differential expression of miR-21, and efficiently opened with short-term exposure to miR-21. Leveraging its autonomous behavior and compact design, the DTO emerges as a promising nanocarrier for various clinically relevant materials. It holds significant application prospects in anti-cancer therapy and the development of flexible biosensors.

Indexed as

3D nanotubeCancer therapyDNA origamiMiR-21Nano-drugOvarian cancer

Identifiers

PMID38495121
PMCPMC10940798

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.